Anne-Marie Laberge, MD, MPH and Wylie Burke, MD, PhD
Two physicians examine the risks of testing minor children for late-onset genetic diseases when there is no current benefit and explain why several medical associations oppose the practice.
Physicians should understand and be sensitive to all of the issues that affect patients when they prescribe the tertogenic medication isotretinoin for treatment of acne vulgaris.
Physicians are cautioned that the two obstacles to reforming post-marketing clinical trials are the FDA's reluctance to revisit past approvals and its inability to enforce pharmaceutical companies' commitment to conduct Phase IV trials.
A physician defends her position that children should only participate in clinical trials when they have child assent and the parents also have been educated about the purpose of the research when there is no direct benefit to the child.
Physicians need to inform parents about the limited effectiveness of growth hormone therapy in satisfying the treatment goals of children with idiopathic short stature.
Physicians need to inform parents about the limited effectiveness of growth hormone therapy in satisfying the treatment goals of children with idiopathic short stature.
Physicians need to inform parents about the limited effectiveness of growth hormone therapy in satisfying the treatment goals of children with idiopathic short stature.